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Abstract
Drugs that target G-protein coupled receptors (GPCRs) represent the primary treatment strategy 
for patients with acute and chronic pain; however, there is substantial individual variability in both 
the efficacy and adverse side effects associated with these drugs. Variability in drug responses is, 
in part, due to individuals’ diversity in alternative splicing of pain-relevant GPCRs. GPCR 
alternative splice variants often exhibit distinct tissue distribution patterns, drug binding properties, 
and signaling characteristics that may impact disease pathology as well as the size and direction of 
analgesic effects. Here, we review the importance of GPCRs and their known splice variants to the 
management of pain.
Pain is a multidimensional sensory and emotional experience that can generally be 
categorized into one of four types1. Nociceptive pain is an acute response to environmental 
stimuli that warns of potential or actual tissue damage. In the event of actual damage, 
inflammatory and/or neuropathic pain may occur. Inflammatory pain occurs in response to 
damage of tissues and infiltration of immune cells, while neuropathic pain occurs in 
response to damage of nerves. Inflammatory and neuropathic pain typically serve to promote 
wound healing and repair; however, in many cases, the pain outlasts the stimulus and 
becomes chronic. Unlike inflammatory and neuropathic pain, functional or idiopathic pain is 
characterized by perpetual abnormalities in sensory processing that occur in the absence of 
direct inflammation or nerve damage.
Acute and chronic pain are primarily treated with pharmacological agents that promote 
analgesia. The principle target of a variety of analgesic drugs including opioids, 
cannabinergics, and anti-depressants is g-protein coupled receptors (GPCRs). Upon 
activation, GPCRs initiate molecular changes resulting in excitation or inhibition of nerve, 
immune, and glial cells important for the onset and maintenance of pain. While the critical 
role of GPCRs in pain biology and management is well established, reliably effective 
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therapeutics with minimal side effects are lacking. Inter-individual variability in response to 
a given analgesic is largely due to variation at the genetic level. Of particular interest are 
genetic variants in alternative splice regions that alter protein coding of the mRNA, giving 
rise to proteins which differ in form and function (i.e., alternative splice variants). This 
review highlights the importance of alternative splicing in the regulation of GPCRs involved 
in the transmission and modulation of pain.
GPCRs are Relevant for the Treatment of Pain
The human genome encodes approximately 800 distinct GPCRs, 70% of which contribute to 
pain or pain-related phenotypes2 .GPCRs interact with a tremendous variety of signaling 
mediators, ranging from small molecules to large peptides and proteins. Although each 
receptor has the ability to induce a range of functional intracellular changes, all GPCRs 
possess a distinct and evolutionarily conserved architecture. Each canonical or classic 
receptor is comprised of seven transmembrane (7TM) proteins that span the cellular 
membrane. These transmembrane proteins are interconnected by intracellular and 
extracellular loops (Figure 1). In addition, there are amino acid chains known as N-terminus 
and C-terminus tails, which are attached to the first and last transmembrane, respectively. As 
alluded by its name, every GPCR is coupled to a g-protein, which acts as a molecular switch 
to regulate cellular activity. (Table 1).
The resulting structure created by the transmembrane segments and loops provides 
interactive sites where ligands can bind. Ligands that bind to their receptor and initiate cell 
signaling are referred to as agonists. Upon binding, agonists produce a conformational 
change of the GPCR and subsequent uncoupling of the associated g-protein. Once 
uncoupled, the g-protein separates into two subunits (the alpha (α) and beta/gamma (β/γ) 
subunits), each of which initiates a chain of molecular reactions that affect cellular activity3. 
Depending on the type of g-protein, the initiated downstream effects can promote cellular 
excitation or inhibition (Table 1). In general, agonists that activate pain-relevant GPCRs 
coupled to Gs typically produce pain, while those coupled to Gi typically inhibit pain2. Other 
ligands, known as antagonists, compete with agonists for the GPCR binding site and impede 
g-protein uncoupling and downstream signaling events. Because of their ability to modulate 
cellular activity at each step of the pain pathway, GPCRs represent a popular pharmacologic 
target for the management of clinical pain. In fact, over 60% of commonly prescribed 
analgesics work by binding to GPCRs3. Table 2 provides a summary of these GPCRs 
(opioid, cannabinoid, adrenergic, and serotoninergic receptors) along with their associated g-
protein, endogenous ligands, and analgesic compounds.
Opioid receptors are among the most well known GPCRs that regulate the transmission and 
perception of pain. There are four opioid receptor subtypes, including: the mu opioid 
receptor (MOR-1), the delta opioid receptor, the kappa opioid receptor, and the nociceptin 
receptor. Of these subtypes, MOR-1 is the classic receptor responsible for analgesic 
responses to endogenous endorphins as well as exogenous drugs. Upon agonist binding to 
MOR-1, its associated Gαi protein is activated and produces cellular inhibition of 
pronociceptive neurons9. For this reason, opioids are used in the management of acute pain 
(such as that associated with surgery) as well as chronic pain disorders such as low back 
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pain, extremity pain, and osteoarthritis10. Opioid antagonists, usually co-administered with 
opioid agonists to reduce the development of unwanted opioid side effects, are also capable 
of producing analgesia independently of MOR-111.
Cannabinoid receptors share similar signaling properties with MOR-1, making them 
attractive targets for clinical pain management. There are two cannabinoid (CB) receptor 
subtypes, CB1 and CB2, both of which couple to Gαi. CB receptors play a significant role in 
promoting analgesia in response to endocannabinoids such as 2-arachidonoylglycerol (2-
AG) and anandamide. Commercially available CB agonists such as nabilone and 
tetrahydrocannabidol, which bind to both CB subtypes, are used to treat fibromyalgia and 
neuropathic pain12.
Adrenergic receptors, which mediate the physiological responses to epinephrine (Epi) and 
norepinephrine (NE), represent another frequently targeted class of GPCRs. The adrenergic 
superfamily includes three subtypes respectively of α 1ARs (α1AAR, α1BAR, α1DAR), 
α2ARs (α2AAR, α2BAR, α2CAR), and βARs (β1ARs, β2ARs, β3ARs). The α2AR couples 
to Gαi and promotes analgesia via cellular inhibition. Hence α2AR agonists such as 
trazodone are used to promote analgesia. In contrast, α 1AR, which is coupled to Gαq, 
facilitates cellular excitation of pronociceptive neurons, resulting in increased pain signaling. 
The βARs also facilitate pain signaling via Gαs signaling. To attenuate their excitatory 
contributions, α1AR and βARs are commonly used to treat a range of chronic pain disorders 
such as migraine, neuropathic pain, and fibromyalgia.
Finally, serotonin receptors, which mediate physiological responses to the monoamine 
serotonin (5-HT) play an important role in pain management8. The serotonin superfamily is 
quite large, including seven general members: 5-HT1 (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-
HT1F), 5-HT2 (5-HT2A, 5-HT2B, 5-HT2C), 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. With 
the exception of the 5-HT3 receptor, a ligand-gated ion channel, all 5-HT receptors are 
GPCRs. The effects of the 5-HT receptor family on pain are heavily dependent upon the 
receptor subtype. Triptans target Gαi-coupled 5-HT1 receptors, which promote analgesia via 
cellular inhibition, and normalize vascular changes associated with migraine headache13. 
Antidepressants promote chronic synaptic serotonin release that causes the downregulation 
of Gαq coupled 5-HT2 receptors, thus attenuating their excitatory contributions to pain 
signaling. 5-HT antagonists that target 5-HT4 receptors in the central nervous system and the 
gastrointestinal (GI) tract are used in the treatment of migraine14 and IBS15. Meanwhile, the 
net effect of 5-HT7 activation on pain is highly dependent on the location of the receptor. 
Activation of 5-HT7 receptors on peripheral nerve terminals produces pain16,17, while 
activation in midbrain structures such as the periaqueductal gray alleviates pain associated 
with nerve injury18.
While these conventional therapeutics are able to alleviate pain, their efficacy is limited to a 
subset of the population19. Additionally, their use is constrained by adverse side effects, such 
as altered mental state, nausea, constipation, sedation, and life-threatening respiratory 
depression. Variability in patient response and side-effect profiles is, in part, due to diversity 
in alternative splicing of GPCRs expressed in tissues that regulate pain processing. By 
expanding our understanding of GPCR alternative splice variants and their associated 
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pharmacodynamic responses, we will be able to better predict patient-centered treatment 
outcomes.
Alternative Splicing Adds to the Diversity of GPCR Signaling
Alternative splicing is an important mechanism of gene regulation, affecting approximately 
90% of all genes within the human genome20. A single gene is able to generate exponential 
protein coding capabilities via alternative splicing. Prior to alternative splicing, a gene is first 
transcribed into precursor messenger ribonucleic acid (pre-mRNA). The pre-mRNA 
sequence contains short protein coding regions known as exons. Interspersed between the 
exons are longer non-coding regions known as introns (Figure 2). Before the sequence can 
be translated to produce protein, the introns and alternative exons within pre-mRNA are 
removed, or spliced, and the constitutive exons are brought together, resulting in the 
canonical mRNA transcript ready for protein synthesis. When alternative splicing occurs, 
however, the pre-mRNA is edited such that constitutive exons are removed from, or introns 
are retained, in the final mRNA transcript. The most common type of alternative splicing 
within the human genome is exon skipping21. Here, constitutive exons are excluded from the 
final mRNA transcript. Another common type of alternative splicing is splice site selection, 
in which the portion of an exon is spliced out due the presence of a nucleotide sequence that 
facilitates splicing activity21. Intron retention is another type of alternative splicing in which 
an intron remains in the final mRNA transcript. Each type of alternative splicing will render 
an mRNA transcript and corresponding protein that is structurally different than the 
canonical protein produced from the standard template.
Accumulating evidence suggests that alternative splicing significantly adds to the functional 
diversity of the human genome and that variations in these processes produce pathological 
states22. The presence of multiple GPCR splice variants allows for essential, precisely 
regulated differences in expression (e.g., tissue-specific expression)23, as well as in agonist 
binding24, agonist-induced internalization25, and intracellular signaling dynamics25,26. Some 
alternative splice variants even display functional characteristics opposite to the canonical 
form27–29 Polymorphisms that alter the ratio of functionally distinct protein isoforms 
through alternative splicing may produce changes in the direction of pain-relevant GPCR 
pharmacodynamics (e.g. coupling to stimulatory vs. inhibitory G protein effector systems), 
yet remain understudied. A PubMed search of “alternative splicing pain” yields only 87 
relevant original research articles. Most are focused on ion channels such as voltage-gated 
calcium channels30 and transient receptor potential channels31,32, with only 12 articles 
focusing on GPCRs. This is an important area of study as identification of GPCR splice 
variants differentially expressed in individuals with altered pain perception and/or analgesic 
responses will help elucidate novel targets for the development of individualized treatment 
strategies.
Functional GPCR Alternative Splice Variants
Examples of alternative splice variants of pain-relevant GPCRs that exhibit diversity in 
expression and signaling profiles include the aforementioned MOR-1, cannabinoid 
receptors, adrenergic receptors, and serotonin receptors. Of additional interest are 
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nociceptin, prostaglandin and neurokinin receptors, which are not targeted by common 
analgesics but are critical for the induction and modulation of pain. Accumulating evidence 
from in vitro, pre-clinical, and clinical studies suggests that alternative splicing of these and 
other GPCR transcripts adds additional layers of complexity to GPCR signaling and 
pharmacodynamics responses. (Table 3).
Opioid receptors
The pharmacologic manipulation of the mu opioid receptor is an essential component of 
clinical pain treatment. Although the signaling characteristics of MOR-1 are well 
established, we are just beginning to understand the complex nature of genetic variants that 
contribute to alternative splicing. At least 20 MOR-1 splice variants have been identified in 
mouse and human genomes25, suggesting an array of potentially functional consequences 
that may occur with opioid administration.
Pre-clinical studies within the past 15 years have begun to reveal the functional properties of 
specific MOR-1 splice variants. Pasternak and coworkers provide evidence that the gene 
expression of MOR-1 splice variants represent compensatory responses to chronic opioid 
administration that stabilize or diminish the development of tolerance90 Other studies have 
shown that the presentation of some unwanted side effects are due to the activation of 
MOR-1 splice variants. For example, Liu and colleagues have demonstrated that because of 
its distinct C-terminus, the splice variant MOR-1D dimerizes with the gastrin-releasing 
peptide receptor in the mouse spinal cord to produce opioid-induced itch33 Another splice 
variant known as MOR-1K, a truncated receptor lacking the N-terminus and first 
transmembrane, has been implicated in the paradoxical increase in pain sensitivity known as 
opioid-induced hyperalgesia (OIH). In contrast to MOR-1 which typically couples to Gαi, 
MOR-1K couples to Gαs to activate adenylyl cyclase (AC) and increase intracellular 
calcium, thus engaging pro-nociceptive signaling events that likely drive OIH29. A 
subsequent preclinical study in mice revealed that genetic knockdown of MOR-1K hindered 
the development of OIH and unmasked opioid analgesia91.
Additional studies investigating the functional characteristics of MOR-1 splice variants 
provide evidence that a set of these receptors promote opioid analgesia by providing 
exclusive binding sites for different opioids. Transgenic mice lacking exon 11, an exon that 
provides an alternative promoter region for the MOR transcript, demonstrated substantial 
reductions in the analgesic efficacies of heroin, fentanyl, and the morphine metabolite 
morphine-6β-glucuronide24, suggesting that exon-11 containing variants play a critical role 
in opioid analgesia. Exon 11-containing splice variants also mediate the analgesic effects of 
iodobenzoylnaltrexamide (IBNtxA), a novel synthetic opioid that produces ten times the 
analgesic efficacy of morphine without producing respiratory distress, dependence, 
tolerance, or GI distress in rodents36,40,92. MOR-1 splice variants also promote analgesia by 
enhancing canonical receptor function. Single-transmembrane splice variants MOR-1R and 
MOR-1S structurally enhance MOR-1 function by stabilizing the canonical 7TM receptor at 
the cellular membrane42. Collectively, these studies highlight the importance of MOR-1 
alternative splice variants in mediating opioid analgesia, as well as side effects such as 
tolerance, itch, and OIH.
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Although few preclinical studies have examined the nociceptin receptor (ORL-1), it may 
also play an influential role in opioid analgesia. Majumdar and colleagues demonstrate that 
the exon 11 splice variant MOR-1G dimerizes with ORL-1 to provide a binding site for 
novel opioid IBNtxA93, suggesting that ORL-1 interacts with MOR-1 splice variants to 
provide specific opioid binding sites. The contribution of ORL-1 to splice variant signaling 
is further complicated by the existence of its own splice variants, ORL-1Long and 
ORL-1Short94. Thus far, ORL-1Short has been implicated in the regulation of the canonical 
receptor, indicating a possible influence over ORL-1 function.
Cannabinoid receptors
Both the CB1 and CB2 receptors undergo alternative splicing to yield variants differing at 
their N-terminal region. The CB1a variant is truncated by 61 amino acids, with the first 28 
amino acids completely different from the canonical CB149. While its tissue distribution 
largely overlaps with that of CB1, CB1a exhibits decreased agonist binding and activity, 
which might be due to a lack of two glycosylation sites typically important for signal 
transduction95. The CB1b variant lacks the first 33 N-terminus amino acids and although it 
overlaps with CB1 in a number of tissues, its abundant expression in fetal brain suggests it 
may play an important role in development48. Similar to CB1a, CB1b exhibits decreased 
agonist binding and activity.
The CB2 variants are generated through the use of alternate promoters located upstream of 
the major coding exon 353. The gene CB2A is initiated from the more distal promoter and 
includes exons 1a and 1b spliced to exon 3, while CB2B is initiated from the more proximal 
promoter and includes exon 2 spliced to exon 3. The CB2A variant is predominantly 
expressed in testes and at lower levels in spleen and brain. In contrast, the CB2B variant is 
predominantly expressed in spleen with very low expression in brain and no expression in 
testes. These tissue-specific distribution patterns may indicate specialized roles for the 
different splice variants with respect to pain modulation, immune response, and 
spermatogenesis.
Adrenergic receptors
Adrenergic receptors play a key role in pain processing as well as cognition and 
cardiovascular function. While α2ARs, β1ARs, and β2ARs are highly relevant to the 
modulation of pain by endogenous and exogenous agonists, the genes encoding these 
receptors are intronless and not subject to alternative splicing. Among the remaining 
adrenergic receptors, the α1AAR subtype has best most extensively studied with respect to 
alternative splicing.
The human α1AAR gene locus is comprised of over 8 exons and codes for 15 known splice 
variants96 The canonical receptor is generated through splicing exon 1 (coding for the N-
terminus and transmembranes [TM] 1 to 6) together with exon 2 (coding for TM7 and the C-
terminus). Four C-terminus splice variants (α1A-2, α1A-3, α1A-4, α1A-5) have been identified 
that are generated through the use of additional acceptor sites at varying locations within, 
and distal to, exon 2. The α1A-2, α1A-3, and α1A-4 variants exhibit ligand binding properties 
and tissue distribution profiles similar to α1AAR, although α1A-3 and α1A-4 are absent in 
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kidney54–57. In contrast to α1AAR that couples to Gαq, these variants couple to Gαi so as to 
inhibit AC activity7. This diversity in α1AAR signaling may contribute to differential 
responses to α1AR antagonists used in the treatment of pain.
In addition, eleven 6TM variants (α1A-6, α1A-7, α1A-8…α1A-16) have been identified that are 
generated through exon skipping. These variants lack TM7 and their C-terminal tails are 
located extracellularly56 The truncated 6TM variants are expressed in similar tissues as 
α1AAR, but are localized exclusively within the cell and unable to bind α1AR agonists or 
directly mediate signal transduction. The 6TM variants do, however, impair α1AAR ligand 
binding and trafficking to the cell surface. Thus, α1AAR 6TM variants likely play a 
significant physiological role by modifying the function and expression of their parent 7TM 
receptors.
One α1BAR splice variant has also been identified in human brain58 The α1BAR protein is 
generated through splicing of exons 1 and 2. In contrast to the canonical receptor, the 
α1B-2AR includes an immediately adjacent sequence following exon 1 in its coding 
sequence and excludes exon 2 that codes for TM7. Tseng-Crank and colleagues also 
identified low levels of a truncated α1DAR transcript, however the result was inconclusive 
and naturally occurring α1DAR variants were not observed58. More work is required to 
determine the potential functional role of α1BAR and α1DAR variants.
The β3AR is primarily known for its ability to regulate energy metabolism and 
thermogenesis58, though evidence for its ability to promote functional and neuropathic pain 
is emerging61,63,97. The gene encoding β3AR undergoes alternative splicing within the 
coding region to yield two C-terminal splice variants differing with respect to tissue 
expression, g-protein signaling profiles, and regulatory properties57,64,98. The β3AAR and 
β3BAR splice variants contain completely unique terminal chains that are 13 and 17 amino 
acids long, respectively. The β3AAR is primarily enriched in fat tissue and couples 
exclusively to Gαs, while the β3BAR is primarily enriched in brain and couples to both Gαs 
and Gαi. In addition, the β3AAR exhibits increased agonist-induced extracellular 
acidification, a measure of cAMP-independent cellular activity. Their unique tissue 
distribution and signaling profiles, together with the known functional role of β3ARs, could 
indicate that β3AARs play a greater role in lipolysis/thermogenesis and that β3BAR in brain 
mediate pain. While these studies were conducted in mouse, it is important to note that the 
human β3AR contains a significant number of genetic variants that are predicted to regulate 
alternative splicing65,66.
Serotonin receptors
Serotonin receptors play a key role in pain processing as well as mood and GI function8 Of 
the 5-HT1 (A, B, D-F), 5-HT2 (A-C), 5-HT4, 5-HT5, 5-HT6, and 5-HT7 GPCR family 
members, the 5-HT2A, 5-HT2C, 5-HT4, 5-HT6, and 5-HT7 receptors are known to undergo 
alternative splicing.
The human 5-HT2 receptor subtypes (5-HT2A, 5-HT2B, and 5-HT2C) couple to Gαq proteins 
to promote the transient release of intracellular calcium. One truncated splice variant of 5-
HT2A (5-HT2A-tr) has been identified that utilizes alternate splice donor and acceptor sites to 
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yield a 3TM receptor with 57 unique amino acids in the C-terminal region64 The 5-HT2A-tr 
is co-expressed with 5-HT2A in most brain tissues, however is unable to couple to the 
calcium pathway. Two truncated splice variants of 5-HT2C (5-HT2CT and 5-HT2C-R-COOHΔ) 
have also been identified. Similar to 5-HT2A-tr, the 5-HT2CT variant utilizes alternate splice 
donor and acceptor sites to yield a 3TM receptor with 19 unique amino acids in the C-
terminal region65 The 5-HT2C-R-COOHΔ variant retains an extra 90 nucleotides from intron 5 
in the TM4 splice site, resulting in a 3TM receptor with a short C-terminus66. Compared to 
the canonical 5-HT2C receptor, the truncated variants exhibit similar expression patterns but 
have impaired 5-HT ligand binding and g -protein coupling65,66. While the relative 
importance of these truncated 5-HT2 splice variants in humans remains unknown, they are 
conserved in rat and mouse66 where their expression levels increase following nerve 
injury99.
The 5-HT4 receptor couples preferentially to Gαs and, while widely expressed, the highest 
levels are found in intestine74. Agonists targeting 5-HT4 are beneficial in alleviating 
abdominal pain associated with irritable bowel syndrome. Of all the 5-HT receptors, 5-HT4 
possesses the greatest diversity in alternative splicing. At least ten splice variants have been 
identified that vary with respect to their tissue distribution and function. Nine C-terminus 
variants (5-HT4a, 5-HT4b, 5-HT4c, 5-HT4d, 5-HT4e, 5-HT4f, 5-HT4g, 5-HT4i, 5-HT4n) have 
been identified that are identical up to amino acid Leu358, after which they vary in sequence 
and length75. Additionally, one variant (5-HT4h) has been identified that includes exon h 
coding for 14 additional amino acids in the second extracellular loop70 The 5-HT4a, 5-HT4b, 
5-HT4c, and 5-HT4e variants are expressed in most tissues, with distribution patterns similar 
to the canonical form74,75. In contrast, the 5-HT4f variant is found in the brain and GI tract, 
but absent in the heart and other tissues22 Meanwhile, the 5-HT4d and 5-HT4h variants are 
expressed exclusively in the GI tract70,72,75. While all of the 5-HT4 splice variants display 
typical ligand binding properties, some show notable functional differences. Both of the GI-
specific 5-HT4d and 5-HT4h variants have a tendency to recognize 5-HT antagonists as 
partial agonists70,78 Furthermore, the 5-HT4d variant exhibits a remarkable 20-fold increase 
in cAMP formation following application of the 5-HT4 agonist renzapride78 The 5-HT4b 
variant is unique in its able to couple to Gαi as well as Gαs proteins, suggesting its diverse 
signaling capabilities in the GI tract, brain, and other tissues68 In the absence of ligand b 
inding, the majority of C-terminus variants exhibits heightened constitutive AC 
activity67,69,73,76–78. The ability of GPCRs to increase basal AC activity has been previously 
reported and can result in physiological functions of the receptor that are largely 
independent of endogenous ligands or exogenous drugs100. Collectively, these studies 
illustrate the high degree of tissue and signaling specificity for a number of 5-HT4 splice 
variants that may be represent attractive targets for the development of new more selective 
drugs for the treatment of irritable bowel syndrome among other conditions.
The 5-HT6 receptor is unique in that it is expressed almost exclusively in the central nervous 
system8. A 3TM splice variant of 5-HT6 (5-HT6-tr) has been identified in brain that is 
generated through different splice donor and acceptor sites80. The corresponding receptor 
includes the TM1–3 and 10 unique amino acids in its C-terminus. In contrast to 5-HT6, the 
expression of 5-HT6-tr is limited to substantia nigra and caudate. The 5-HT6-tr receptor is 
able to translocate to the membrane, yet unable to bind serotonin. This splice variant may 
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have a yet-to-be-determined function or be indicative of abnormalities due to pathologic 
state.
The 5-HT7 receptor is expressed on primary afferent nociceptors, as well as in pain-relevant 
brain regions where it couples to Gαs to mediate the transmission and modulation of pain. 
Three splice variants of 5-HT7 (5-HT7a, 5-HT7b, 5-HT7d) have been identified that are all 
generated through alternative splicing of the second intron located near the C-terminal 
coding region. The 5-HT7a and 5-HT7b variants have tissue expression profiles and 
functional characteristics similar to the canonical receptor, though 5-HT7b has been shown to 
exhibit significantly higher constitutive AC activity when expressed in stable cell lines101. 
The 5-HT7d variant is predominantly expressed in smooth muscle tissues such as the heart 
and GI tract82 and displays unique functional characteristics. Compared to the canonical 5-
HT7 receptor and the 5-HT7a and 5-HT7b variants, the 5-HT7d variant displays agonist-
independent internalization (even in the presence of antagonist) and associated reductions in 
agonist-induced AC activity85. It has been suggested that differences in the functional 
characteristics of 5-HT7 variants is due to specific features of their carboxyl tails, leading to 
differential interactions with protein partners that mediate their activity, trafficking, and/or 
internalization85,102
Prostaglandin E Receptor 3
Prostaglandins, such as prostaglandin E2, are a product of cyclooxygenase (COX) that 
facilitate pain transmission through binding to the prostaglandin E receptor 3 (EP3 receptor). 
Activation of the Gαi-coupled EP3 receptor has been shown to produce analgesia103, but also 
to promote HIV-induced inflammation104 and sensitization of trigeminal nociceptors105. 
These contradictory effects may be due to the presence of EP3 splice variants. Six C-
terminus splice variants (EP3A…F) have been identified, to date. Of these, the EP3C receptor 
exhibits the most unique signaling characteristics as it is able to couple to Gαs as well as 
Gαi86. The dual coupling of the EP3C variant to different g-proteins may explain the ability 
of EP3 ligands to produce both analgesia and hyperalgesia.
Neurokinin-1 Receptor
Neurokin-1 receptors (NK-1Rs) are targets for the endogenous pro-pain ligand substance P. 
Their activation results in Gαq-mediated increases in intracellular calcium levels and 
production of pro-inflammatory cytokines89 Alternative splicing of the NK-1R yields a 
truncated variant (NK-1Rtruncated) that lacks the C-terminus and has functional properties 
that differ from the canonical receptor. Unlike NK-1R, activation of the NK-1Rtruncated 
variant does not result in increased levels of calcium or nuclear activity of factor-κB (NF-
κB). Instead, activation of NK-1Rtruncated results in decreased phosphorylation of protein 
kinase C (PKC) and levels of interleukin-8. A recent clinical study has demonstrated the 
utility of an NK-1R antagonist in the treatment of chronic pain conditions and anxiety106. 
Results from functional studies of the NK-1Rtruncated variant suggest that splice variant-
specific agonists may also be useful for pain management.
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Clinical Relevance of Functional Gene Regulatory Events
Given the extensive list of alternative GPCR splice variants and their known impact on 
signaling and pharmacodynamics, it is expected that these variants have important clinical 
implications for pain management. Major strides in both preclinical and clinical research are 
still needed before we can reliably predict a patient’s treatment response based on their 
splice variant expression profile. Such strides have been made, however, in the study of 
another type of gene variation, single nucleotide polymorphisms (SNPs). Like alternative 
splicing, SNPs within key pain-related genes can result in changes that subsequently affect 
the encoded protein. For example, SNPs in the gene encoding catechol-o-methyltransferase 
(COMT; an enzyme that metabolizes catecholamines) are indicative of abnormalities in 
COMT function and predictive of chronic pain risk and treatment response. Human genetic 
association studies have shown that the rs4680 SNP, alone or in combination with other 
nearby SNPs, is predictive of temporomandibular disorder (TMD) and fibromyalgia 
onset107,108. Subsequent molecular studies demonstrated that these SNPs alter the 
thermostability and/or structure of the COMT transcript109, explaining why patients with 
functional pain disorders110–112 and exacerbated postoperative pain113–116 exhibit decreased 
levels of COMT alongside increased levels of catecholamines. Preclinical studies further 
revealed that elevated levels of epinephrine/norepinephrine resulting from low COMT 
activity, lead to increased pain through activation of βARs117,118. Coming full circle, results 
from a randomized controlled trial demonstrated that the βAR antagonist propranolol 
provides significant pain relief for pain patients who carry the SNPs associated with 
decreased levels of COMT119. Together, these findings highlight the impact of gene 
regulation on pain as well as the utility of genetic and protein biomarkers in identifying a 
subgroup of patients who will benefit from specific therapies.
In a similar fashion, we believe that measurement of alternative GPCR splice variants can be 
used as a diagnostic tool to provide personalized pain treatment. This is already being done 
in cancer. In vitro studies examining the role of NK-1R alternative splicing in breast cancer 
cells demonstrated that overexpression of the NK-1Rtruncated variant promotes 
tumorigenesis120,121. A complementary clinical study further demonstrated that individuals 
with overexpression of the NK-1Rtruncated variant were at increased risk for colitis-
associated carcinoma, while expression levels of the canonical NK-1R remained consistent 
between cases and controls122.
Just as the study of alternative splicing is beginning to inform diagnosis and management of 
patients with cancer, the study of alternative splicing in pain-relevant GPCRs has great 
potential to advance the current state of clinical care for patients with chronic pain. 
Additionally, this line of inquiry may lead to the advent of new pain therapies such as 
IBNtxA, a novel opioid analgesic specifically targeting 6TM mu opioid splice variants123.
Conclusion
G-protein coupled receptors play a major role in modulating the activity of a chorus of cells 
involved in the transmission, modulation and perception of pain. For this reason, GPCRs are 
the primary target of many pharmacologic interventions used in the management of acute 
Oladosu et al. Page 10













and chronic pain. Nonetheless, the use of these medications is limited due to variability in 
analgesic efficacy and side effect profiles. These limitations are partly attributed to genetic 
differences that influence alternative splicing of pain-relevant GPCRs. The functional 
importance and implications of the diversity of GPCRs in contributing to the 
pathophysiology of clinical pain is just beginning to emerge. More research, especially in 
the clinical arena, is necessary to further investigate the functions of specific GPCR splice 
variants, as well as the dynamic interactions between multiple variants of the same canonical 
receptor, within the context of pain. This line of inquiry will evolve our understanding of 
pain mechanisms and inform the design of new and clinically useful drugs that target 
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3. What is the most common form of alternative splicing in humans?
a. Intron Retention
b. Exon Skipping
c. Alternative 3’ Splice Site
d. Alternative 5’ Splice Site
e. Exon Retention
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5. The α1A-2, α1A-3, and α1A-4 variants exhibit the same binding capabilities 
as the α1A receptor. Unlike the canonical receptor, these splice variants 
couple to Gαi instead of Gαs. This change in g-protein coupling is due to 
alternative splicing of what receptor region?
a. N-terminus
b. Extracellular loop 1
c. C-terminus
d. 1st transmembrane
e. Intracellular loop 1
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Learning Objectives: On completion of this article, you should be able to (1) explain the 
importance of GPCRs to pain signaling and modulation; (2) explain the basic concepts of 
alternative splicing; and (3) describe how individual variability in alternative splicing of 
GPCRs may contribute to variability in the nature of pain as well as responses to 
analgesic drugs.
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GPCR structure and function. A) A g-protein coupled receptor (GPCR) is composed of 
seven transmembranes (grey) interconnected by three intracellular (orange) and three 
extracellular (purple) loops. On the end of the first and last transmembrane are the N-
terminus (blue) and C-terminus (red), respectively. As its name suggests, a GPCR is bound 
to a tri-meric g-protein composed of alpha (α) and beta/gamma (β/γ) subunits. B) When a 
ligand (black) binds to a GPCR, the associated g-protein separates into the α and β/γ 
subunits. These subunits then stimulate a variety of downstream effectors that produce 
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changes in cellular activity (see Table 1). Abbreviations: GPCR = G-Protein Coupled 
Receptor
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Different types of alternative splicing. The most common type of alternative splicing in 
animals is A) exon skipping, in which a constitutive exon is spliced from the final mRNA 
transcript. Alternative B) 3’ and C) 5’ splice sites provide additional junctions within an 
exon, resulting in partial splicing of the exonic mRNA sequence. D) Intron retention is a rare 
type of alternative splicing that occurs when an intron remains within the final mRNA 
transcript. Abbreviations: mRNA = Messenger Ribonucleic Acid
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Structural variations in GPCRs as a result of alternative splicing. Exons within the mRNA 
transcript serve as coding regions for specific sections of protein. Alternative splicing events 
that change or remove exonic sequences can produce GPCR splice variants with 
corresponding changes in protein composition and/or structure. A) For example, splicing 
events that lead to alterations in exon 1 can yield GPCRs with truncated N-termini that affect 
ligand binding, while events that lead to alterations in exon 4 can yield GPCRs with 
truncated C-termini that affect g-protein coupling and signaling. B) Splicing events can also 
lead to skipping of an exon that codes for an unit of the GPCR, such as a transmembrane, 
thus yielding a truncated GPCR lacking the encoded section, such as a 6 transmembrane 
(6TM) splice variant. Abbreviations: GPCR = G-Protein Coupled Receptor; TM = 
Transmembrane
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Table 1
Common G-proteins and Their Intracellular Effects.
G protein Effectors Overall Impact
Gαs activates adenylyl cyclase → ↑ cAMPa cellular excitation (pro-nociceptive)
Gαq activates PLCβ → ↑ intracellular Ca++ levels cellular excitation (pro-nociceptive)
Gαi/o inhibits adenylyl cyclase → ↓ cAMP cellular inhibition (anti-nociceptive)
a
Abbreviations: cAMP = cyclic adenosine monophosphate; Ca = calcium; PLCβ = phospholipase C β.
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Table 3




protein Tissue Distribution Functional Characteristics
Opioid Receptors
MOR-1 Gαi4 brain, spinal cord > adrenal gland > small
C-term intestine34
variants OP binding → analgesia38
MOR-1A brain35 OP binding → analgesia38
MOR-1B brain35 OP binding → analgesia38
MOR-1C brain35; agonist-induced reduction36 OP induced itch33
MOR-1D Gαi33 brain35 OP binding → analgesia38







MOR-1X brain35 OP binding → analgesia39
MOR-1Y brain35
N-term Novel opioid binding40
variants brain35 OP binding → analgesia41
MOR-1G brain35 OP binding → analgesia41
MOR-1H brain35 OP binding → analgesia41
MOR-1I brain35 contributes to OIH





Single TM brain35 Stabilization of MOR-142




MOR-1T brain (human neuroblastoma cell line)37 ?
MOR-1Z brain (human neuroblastoma cell line)37
MOR-1SV1
MOR-1SV2

















protein Tissue Distribution Functional Characteristics
ORL-1 Gα i43 brain, immune cells, GI tract44
ORL-1Short brain > testis > heart, kidneys, muscle, ↓ agonist binding46
ORLLong spleen, thymus45
brain > testis > muscle, spleen45
?
Cannabinoid Receptors
CB1 Gα i5 brain, sc, DRG > pituitary > heart, lung,
uterus, testis, spleen, tonsils47
N-term
variants ↓ agonist binding, ↓GTPγS activity48
CB1a similar distribution to CB1+ kidney48,49 ↓ agonist binding, ↓GTPγS activity48
CB1b fetal brain > GI tract, uterus, muscle > adult
brain48




CB2A testis > spleen, leukocytes > brain53 ?
CB2B spleen > leukocytes53
Adrenergic Receptors
α1A Gαq6 liver, heart, brain > prostate, kidney, bladder6
C-term
variants
Gα i7 liver, heart > prostrate, kidney54,55 pharmacology similar to α1A7,54,55,57
α 1A-2 Gα i7 liver > heart, prostrate (absent in kidney)54,55





liver, heart, hippocampus, and prostate;
expressed intracellularly56






























protein Tissue Distribution Functional Characteristics
α1B Gαq6 liver, heart, brain (including cortex) 6
6TM variant
(−TM7) expressed in hippocampus, but absent in ?
α 1B-2 cortex58
β3 Gαs, fat, immune cells/tissues > GI tract, DRG59,62
Gα i59,60
C-term
variants fat > ileum > brain63 ?
β3a (mouse) Gαs7,61 brain > fat, ileum63 ?
β3b (mouse) Gαs,Gαi7,61
Serotonin Receptors
5-HT2A Gαq8 cortex, hippocampus, brainstem, olfactory >
basal ganglia, limbic8
6TM variant (−TM4) impaired 5-HT-induced Ca++ signaling64
5-HT2A–tr hippocampus, caudate, corpus collosum,
amygdala, substania nigra64




choroid plexus, striatum, hippocampus,
hypothalamus, olfactory, sc65
impaired 5-HT ligand binding65
C-term variant impaired 5-HT ligand binding66
5-HT2AC-R-
COOHΔ
sc, cortex, cerebellum, medulla, caudate,
amygdala, corpus collosum66
5-HT4 Gαs8 intestine > brain > pit > uterus, testis > 
spleen
> heart, kidney, lung, sc74
C-term variants Gαs67 ↑ constitutive AC activity, ↑ 
isomerization, ↓
5-HT4a Gαs, intestine, brain > pit > uterus, testis > heart > agonist internalization76,77
5-HT4b Gαi67,68 spleen, lung, sc74 ↑ constitutive AC activity67
5-HT4c Gαs67 intestine, brain > pit > uterus > heart, spleen, ↑ constitutive AC activity67
5-HT4d Gαs67 lung, sc74 20-fold ↑ in agonist-induced cAMP 
activity78
5-HT4e Gαs69 intestine > pit > brain > uterus, testis, heart, ↑ constitutive AC activity69
5-HT4f Gαs70 spleen, sc74 ?
5-HT4g Gαs71 ileum, colon, but absent in brain73,75 ?
5-HT4i Gαs72 brain > testis > sc > intestine, pit, heart, ↑ constitutive AC activity79
5-HT4n Gαs73 prostate ileum, colo75
brain, ileum, colon75
2nd EL loop brain, heart, ileum, colon75
variant Gαs70 brain, ileum, colon, heart75 antagonist GR113808 acts as partial

















protein Tissue Distribution Functional Characteristics
5-HT4h brain, heart, oesophagus75
GI tract70
agonist70
5-HT6 Gαs8 cortex, hippocampus, olfactory, striatum,
amygdala, acumbens8
6TM variant (−TM4) impaired binding to 5-HT and LSD80
5-HT6-tr cortex, hippocampus, cerebellum, thalamus,
substantia nigra, caudate80





5-HT7a Gαs82 brain, heart, GI tract, spleen, lung, ↑ constitutive AC activity82
5-HT7b Gαs82 astrocytoma, glia81,83,84 exhibit agonist-independent internalization85
5-HT7d brain, heart, GI tract, spleen, lung,
astrocytoma, glia82–84
heart, GI tract, ovary, testis, spleen, lung,
astrocytoma83
Prostaglandin E Receptors
EP3 Gα i86 Kidney> uterus>stomach> brain, thymus,
heart, spleen86
C-term
variants Gα i, ↓ constitutive AC activity86
EP3A/I Gα1286 ? ↓ AC activity86
EP3B/II Gα i, ? ↓ or ↑ constitutive AC activity86
EP3C/III Gα1286 ? ?
EP3D Gαi, Gαs86 ? ?




NK-1R Gαq/1187 brain, GI tract, lung, thyroid, immune cells88
NK-1Rtruncated ? ? Impaired SP-induced calcium release89
Abbreviations: 5-HT = serotonin;AC = adenylyl cyclase; N-term = amino terminus; Ca++ = calcium; C-term = carboxyl terminus; cAMP = cyclic 
adenosine monophosphate; EL = extracellular loop; GI = gastrointestinal; LSD = lysergic acid
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